Cipla and Lilly partner to expand tirzepatide access in India

Cipla Limited has announced a marketing and distribution agreement with Eli Lilly and Company (India) Private Limited for a second brand of tirzepatide in India. Cipla will market the molecule under the brand name Yurpeak, expanding its availability beyond the cities where Lilly currently has a presence. Lilly will manufacture and supply Yurpeak to Cipla, with pricing consistent with Lilly's previously launched tirzepatide brand, Mounjaro, introduced in March 2025.

Tirzepatide is a prescription-based dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. The product's launch is contingent on receiving the necessary regulatory approvals.

India faces a significant health challenge with approximately 101 million people living with diabetes and a rising prevalence of obesity, affecting nearly 100 million adults as of 2023. This partnership aims to enhance patient access to innovative therapeutic options for these chronic conditions. Yurpeak will be available in the KwikPen presentation across six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg.